| Followers | 934 |
| Posts | 159778 |
| Boards Moderated | 2 |
| Alias Born | 08/13/2010 |
Wednesday, April 01, 2026 5:11:48 PM
$JAZZ is in YOLO – AdvisorShares Pure Cannabis ETF
What it really focuses on
$YOLO is more of a hybrid: it mixes U.S. cannabis, Canadian LPs, and related plays, and even holds MSOS itself:
MSOS: YOLO’s largest position is actually MSOS, giving it indirect exposure to the same U.S. MSOs.
High Tide, Village Farms, SNDL, Cronos, Organigram, Canopy: These are Canadian-listed or global cannabis operators, giving YOLO international and retail-oriented exposure.
Jazz Pharmaceuticals, Cardiol Therapeutics, Chicago Atlantic, AFCG: These add pharma/biotech and cannabis-focused lending/REIT exposure, diversifying away from pure plant-touching risk.
$TLRY appears as a mid-sized position alongside these names.
What it really focuses on
$YOLO is more of a hybrid: it mixes U.S. cannabis, Canadian LPs, and related plays, and even holds MSOS itself:
MSOS: YOLO’s largest position is actually MSOS, giving it indirect exposure to the same U.S. MSOs.
High Tide, Village Farms, SNDL, Cronos, Organigram, Canopy: These are Canadian-listed or global cannabis operators, giving YOLO international and retail-oriented exposure.
Jazz Pharmaceuticals, Cardiol Therapeutics, Chicago Atlantic, AFCG: These add pharma/biotech and cannabis-focused lending/REIT exposure, diversifying away from pure plant-touching risk.
$TLRY appears as a mid-sized position alongside these names.
Nothing I post is financial advice. I may hold long, short, or no positions in mentioned securities. I’ve never been paid to post. All content is for entertainment purposes only.
Recent JAZZ News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:27:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2026 08:13:14 PM
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/12/2026 08:15:00 PM
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/12/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:06:23 PM
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:05:00 PM
- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results • PR Newswire (US) • 05/05/2026 08:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:19:10 PM
- Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA • PR Newswire (US) • 04/27/2026 11:45:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/24/2026 08:09:04 PM
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 • PR Newswire (US) • 04/21/2026 08:15:00 PM
- Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 • PR Newswire (US) • 04/21/2026 08:15:00 PM
- Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) • PR Newswire (US) • 04/21/2026 08:05:00 PM
- Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting • PR Newswire (US) • 04/09/2026 11:45:00 AM
- Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference • PR Newswire (US) • 04/01/2026 08:15:00 PM
- American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education • PR Newswire (US) • 03/24/2026 05:49:00 PM
- Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 • PR Newswire (US) • 03/18/2026 11:44:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:27:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:25:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:21:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:15:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:10:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:07:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:26:33 PM
